OSAKA, Japan–(BUSINESS WIRE)–Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced that it has completed the acquisition of IntraBio Inc. (“IntraBio”). The acquisition adds AQNEURSA® (levacetylleucine) and additional rare disease capabilities to Shionogi’s growing global portfolio. AQNEURSA was approved by the U.S. Food and Drug Administration in 2024 and by the European Medicines Agency (EMA) in January 2026 for n

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.